FATE THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.205 USD | +3.06% |
|
+0.36% | +13.24% |
| May. 10 | Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating | MT |
| May. 10 | Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating | MT |
Presenter SpeechPeter Lawson (Analysts)Good afternoon, everyone and welcome to Barclays Global...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Companyâs platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.
Calendar
2024-07-30
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
4.08
USD
Average target price
6.933
USD
Spread / Average Target
+69.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.24% | 464M | |
| +4.86% | 109B | |
| +11.01% | 105B | |
| -0.38% | 22.25B | |
| -11.89% | 22.09B | |
| -7.66% | 18.68B | |
| -36.52% | 17.58B | |
| -10.01% | 16.85B | |
| +3.69% | 13.76B | |
| +35.80% | 12.46B |
- Stock Market
- Equities
- FATE Stock
- News Fate Therapeutics, Inc.
- Transcript : Fate Therapeutics, Inc. Presents at Barclays Global Healthcare Conference, Mar-14-2023 03
